GlassScriptPhysician profile
Heather A Van Laten
NPI 1619216264
$3,132.98
in general payments reported to CMS, 2019-2025
36 companies · $718 in 2025
The $718 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $270 · 2023: $681 · 2024: $546 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.27 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $381.32 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $358.79 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $278.52 | 2021 | |
| Pfizer INC. | $156.66 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $155.32 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $153.48 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $152.26 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.01 | 2023-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $133.77 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $109.13 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $82.43 | 2022-2025 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $70.03 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $68.72 | 2024 | Veozah |
| Exact Sciences Corporation | $47.96 | 2024 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $40.22 | 2023-2024 | Givlaari |
| Dexcom, INC. | $29.14 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $24.66 | 2024 | Eterna |
| Agios Pharmaceuticals, INC. | $23.00 | 2025 | Pyrukynd |
| Halozyme INC | $22.54 | 2023 | |
| Organon LLC | $22.29 | 2025 | Nexplanon |
| Phadia US INC. | $19.59 | 2023 | Immunocap |
| Vertex Pharmaceuticals Incorporated | $19.29 | 2025 | |
| Sanofi Pasteur INC. | $18.40 | 2023 | |
| Madrigal Pharmaceuticals | $18.11 | 2025 | Rezdiffra |
| Avanir Pharmaceuticals, INC. | $17.90 | 2022 | |
| Indivior INC. | $17.54 | 2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $15.25 | 2021 | |
| Antares Pharma, INC. | $14.94 | 2021 | |
| Exeltis, USA INC. | $14.72 | 2023 | Slynd |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $14.53 | 2024 | Unithroid |
| Vivaquant INC, Dba Rhythm Express | $14.28 | 2025 | Rhythm Express |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.09 | 2021 | |
| Genentech USA, INC. | $8.71 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.43 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Van Laten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.